Efficacy News and Research

RSS
Fibromyalgia drug to earn 38% patient share in the U.S. and 30% patient share in Europe

Fibromyalgia drug to earn 38% patient share in the U.S. and 30% patient share in Europe

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Sumavel DosePro and Levadex to earn up to $400M by 2018

Sumavel DosePro and Levadex to earn up to $400M by 2018

UCSB research: Rapamycin drug, a potential treatment for ADPKD

UCSB research: Rapamycin drug, a potential treatment for ADPKD

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes

Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes

ERYtech Pharma receives ODD for its GRASPA from FDA

ERYtech Pharma receives ODD for its GRASPA from FDA

YM BioSciences' nimotuzumab Phase II trials: FDA advises patient enrollment

YM BioSciences' nimotuzumab Phase II trials: FDA advises patient enrollment

Spectrum Pharmaceuticals to submit additional data for FUSILEV sNDA

Spectrum Pharmaceuticals to submit additional data for FUSILEV sNDA

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

Biovail comments on Teva Pharmaceutical's proposed Budeprion XL trial

Biovail comments on Teva Pharmaceutical's proposed Budeprion XL trial

USPTO issues new patent for Advaxis' intellectual property portfolio

USPTO issues new patent for Advaxis' intellectual property portfolio

Data from GenVec's trial in esophageal cancer showcased at 2010 Gastrointestinal Cancer Symposium

Data from GenVec's trial in esophageal cancer showcased at 2010 Gastrointestinal Cancer Symposium

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

hESC "reporter" line to measure endothelial cell production and activity

hESC "reporter" line to measure endothelial cell production and activity

Norepinephrine responses to bucindolol influenced by alpha-2C adrenergic receptor genotype

Norepinephrine responses to bucindolol influenced by alpha-2C adrenergic receptor genotype

CytRx announces its plans to advance multiple oncology development programs in 2010

CytRx announces its plans to advance multiple oncology development programs in 2010

NicOx receives EMEA approval for naproxcinod MAA

NicOx receives EMEA approval for naproxcinod MAA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.